Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY) Healthcare & Pipeline Overview

Relay Therapeutics is a clinical-stage biotechnology firm pioneering precision medicines through advanced computational techniques, targeting oncology and genetic diseases. Their innovative approach to small molecule drug discovery, coupled with strategic collaborations, positions them uniquely within the competitive biopharmaceutical landscape, addressing significant unmet medical needs.

What Is the Investment Thesis for RLAY?

Relay Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative approach to drug discovery and promising clinical pipeline. The company's focus on precision medicines, particularly in targeted oncology, addresses a significant unmet medical need. Key value drivers include the advancement of RLY-4008 through clinical trials, with potential for accelerated approval based on early efficacy data. The ongoing Phase 1 trial of RLY-1971 and the development of RLY-2608 also contribute to the company's growth prospects. However, the investment is subject to risks inherent in clinical-stage biotechnology companies, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $3.28B and a negative profit margin of -2554.1%, Relay Therapeutics' financial performance is heavily dependent on the successful development and commercialization of its drug candidates. The company's high beta of 1.58 indicates higher volatility compared to the market, reflecting the speculative nature of biotechnology investments. Successful execution of clinical programs and strategic partnerships will be critical for realizing the company's long-term value.

Based on FMP financials and quantitative analysis

RLAY Key Highlights

• Market Cap of $3.28B reflects investor confidence in Relay Therapeutics' pipeline and precision medicine approach.
• Gross Margin of 89.7% indicates strong potential profitability upon successful commercialization of drug candidates.
• Profit Margin of -2554.1% highlights the significant R&D investment typical of clinical-stage biotechnology companies.
• Lead product candidate RLY-4008 is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors, representing a key milestone.
• Collaboration with Genentech, Inc. for the development and commercialization of RLY-1971 validates Relay Therapeutics' technology and approach.

Who Are RLAY's Competitors?

RLAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RLAY's Key Strengths?

• Innovative drug discovery platform integrating computational and experimental approaches.
• Promising pipeline of targeted therapies in clinical development.
• Strategic collaborations with leading pharmaceutical companies.
• Strong intellectual property portfolio.

What Are RLAY's Weaknesses?

• Clinical-stage company with no currently marketed products.
• High R&D expenses and negative profit margins.
• Reliance on successful clinical trial outcomes and regulatory approvals.
• Competition from established pharmaceutical companies and other biotech firms.

What Could Drive RLAY Stock Higher?

• Data readouts from the Phase 1 clinical trial of RLY-1971 in patients with advanced solid tumors.
• Initiation of Phase 2 clinical trials for RLY-4008 in FGFR2-altered solid tumors.
• Enrollment and progression of patients in the first-in-human clinical trial of RLY-4008.
• Continued development and optimization of RLY-2608 targeting mutant-PI3Ka.

What Are the Key Risks for RLAY?

• Negative return on equity (-43.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in the development of Relay Therapeutics' drug candidates.
• Regulatory setbacks or changes in the regulatory landscape.
• Competition from other targeted therapies and established pharmaceutical companies.
• High R&D expenses and negative profit margins.
• Dependence on successful collaborations with partners like Genentech.

What Are the Growth Opportunities for RLAY?

• Expansion of RLY-4008 into Additional FGFR2-Altered Tumor Types: RLY-4008, currently in Phase 1 trials for FGFR2-altered solid tumors, has the potential to expand into other tumor types harboring FGFR2 alterations. This expansion could significantly increase the addressable patient population and market opportunity. The FGFR2 inhibitor market is projected to grow as precision medicine advances, offering Relay Therapeutics a substantial growth avenue. Success in these trials and subsequent regulatory approvals could drive significant revenue growth.
• Advancement of RLY-2608 Targeting Mutant-PI3Ka: RLY-2608, a mutant-PI3Ka inhibitor, represents a significant growth opportunity in addressing cancers driven by PI3K mutations. The PI3K pathway is frequently dysregulated in various cancers, making it a high-value drug target. Positive clinical data and regulatory approval could position RLY-2608 as a key therapy in this space, capturing a significant share of the PI3K inhibitor market. This market is expected to expand as more precise diagnostic tools identify patients who could benefit from PI3K-targeted therapies.
• Development and Commercialization of RLY-1971 Through Genentech Collaboration: The collaboration with Genentech for RLY-1971 provides Relay Therapeutics with a strong partner for development and commercialization. RLY-1971, an SHP2 inhibitor, targets a key signaling pathway in cancer. Genentech's expertise and resources can accelerate the development and market penetration of RLY-1971, generating milestone payments and royalties for Relay Therapeutics. This partnership de-risks the development process and provides a pathway to commercial success.
• Expansion into New Therapeutic Areas Beyond Oncology: While Relay Therapeutics' initial focus is on oncology, the company's platform and expertise in precision medicine can be leveraged to expand into other therapeutic areas, such as genetic diseases and autoimmune disorders. These areas represent significant unmet medical needs and market opportunities. By applying its computational modeling and drug discovery capabilities to new targets, Relay Therapeutics can diversify its pipeline and revenue streams, reducing its reliance on oncology-specific products.
• Strategic Partnerships and Acquisitions to Expand Pipeline: Relay Therapeutics can pursue strategic partnerships and acquisitions to expand its pipeline and access new technologies. Collaborating with or acquiring companies with complementary expertise or promising drug candidates can accelerate the company's growth and enhance its competitive position. These partnerships can provide access to new targets, technologies, and markets, driving long-term value creation.

What Opportunities Does RLAY Have?

• Expansion of existing drug candidates into new indications.
• Development of new therapies targeting additional genetic mutations and signaling pathways.
• Strategic partnerships and acquisitions to expand pipeline and access new technologies.
• Growth in the precision medicine market.

What Threats Does RLAY Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other targeted therapies.
• Changes in the regulatory landscape.
• Economic downturns and market volatility.

What Are RLAY's Competitive Advantages?

• Proprietary computational platform for drug discovery: Relay Therapeutics' platform integrates advanced computational techniques, including protein motion analysis, to design novel therapies.
• Strong intellectual property portfolio: The company has patents covering its drug candidates and platform technologies.
• Strategic collaborations with leading pharmaceutical companies: Partnerships with companies like Genentech provide access to resources and expertise.
• Focus on precision medicine: Relay Therapeutics' focus on targeted therapies addresses a growing market need.

What Does RLAY Do?

Relay Therapeutics, Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company was initially known as Allostery, Inc., before rebranding to Relay Therapeutics to better reflect its mission. Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery, particularly in targeted oncology and genetic disease indications. Their core strategy involves integrating advanced computational techniques, including protein motion analysis, to design and develop novel therapies. Relay Therapeutics' pipeline includes several promising product candidates. RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), is currently in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors. RLY-2608 is a lead mutant-PI3Ka inhibitor program targeting phosphoinostide 3 kinase alpha. RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase SHP2, is in Phase 1 trial for patients with advanced solid tumors. These programs reflect the company's commitment to developing targeted therapies that address specific genetic mutations and signaling pathways driving disease progression. Relay Therapeutics has established strategic collaborations to support its research and development efforts. A collaboration and license agreement with D. E. Shaw Research, LLC allows Relay to leverage computational modeling capabilities focused on protein motion analysis to discover and develop compounds. Another collaboration with Genentech, Inc. focuses on the development and commercialization of RLY-1971, highlighting the company's ability to attract partnerships with leading pharmaceutical companies. With a focus on precision medicine and a robust pipeline, Relay Therapeutics aims to deliver transformative therapies for patients with cancer and genetic diseases.

What Products and Services Does RLAY Offer?

• Develops precision medicines targeting specific genetic mutations and signaling pathways.
• Utilizes advanced computational techniques, including protein motion analysis, to design novel therapies.
• Focuses on small molecule drug discovery for targeted oncology and genetic disease indications.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Collaborates with leading pharmaceutical companies and research institutions to advance its pipeline.
• Aims to transform the drug discovery process by integrating computational and experimental approaches.
• Develops oral small molecule inhibitors for various cancer targets.

How Does RLAY Make Money?

• Develops and patents novel drug candidates targeting specific disease-causing proteins.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments, royalties on sales of commercialized products, and direct sales of approved drugs.
• Invests heavily in research and development to discover and advance new drug candidates.

What Industry Does RLAY Operate In?

Relay Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The precision medicine market, estimated to reach $141.83 billion by 2032, is a key growth area, driven by advancements in genomics and targeted therapies. Relay Therapeutics' focus on small molecule drug discovery and computational modeling positions it to capitalize on this trend. The company competes with both large pharmaceutical companies and smaller biotech firms developing targeted therapies for oncology and genetic diseases. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.

Who Are RLAY's Key Customers?

• Patients with advanced or metastatic solid tumors harboring specific genetic alterations (e.g., FGFR2 alterations).
• Oncologists and other healthcare professionals who prescribe targeted therapies.
• Pharmaceutical companies that partner with Relay Therapeutics to develop and commercialize drug candidates.
• Hospitals and cancer centers that use Relay Therapeutics' drugs to treat patients.

How Relay Therapeutics, Inc. Is Valued

Relay Therapeutics, Inc. carries a market capitalization of $3.28B, placing it in the mid-cap category. Relative to its peer group, RLAY's quantitative score of 24/100 is below the peer average of 72/100.

ROE -44%Key Financial Metrics

Return on equity for Relay Therapeutics, Inc. stands at -43.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Relay Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 29.73 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Relay Therapeutics, Inc. revenue of about $12.6M for fiscal 2026, with EPS near $-1.55. The estimate reflects 8 contributing analysts.

RLAY Financials

RLAY Latest News

RLAY Analyst Consensus

RLAY MoonshotScore

Latest Relay Therapeutics, Inc. Analysis

Common Questions About RLAY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources